Oncology Nursing News®, a digital and print media enterprise dedicated to bringing the oncology nursing community together by providing them with the latest nursing news, clinical insights and resources, welcomes registered nurse Deborah A. Boyle as its editor in chief following the retirement of Lisa Schulmeister.
The Food and Drug Administration (FDA) expanded the approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy to include first-line use in newly diagnosed adult and pediatric patients aged 2 years and older with severe aplastic anemia.
The clinical trials program at the Lehigh Valley Cancer Institute grew exponentially in a short period of time. A great problem to have, certainly, but challenging to the organization.
The Food and Drug Administration (FDA) has approved the use of brentuximab vedotin (Adcetris) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL).
The Food and Drug Administration (FDA) has granted a breakthrough therapy designation to brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the first-line treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
Sexuality after cancer is an under-discussed topic between healthcare providers and patients, and nurses especially have an important role to play in raising the subject with patients, according to Anne Katz, PhD, RN, FAAN.
Scientists, physicians and patients collaborate to improve treatment for rare cancer.
The Aplastic Anemia & MDS International Foundation (AAMDSIF), the world's leading non-profit health organization dedicated to serving patients afflicted with bone marrow failure disease, announced today that Neil Horikoshi has been named the Foundation's new Chief Executive Officer and Executive Director.
The Food and Drug Administration (FDA) granted a priority review to atezolizumab (Tecentriq) in combination with nab-paclitaxel (Abraxane) for frontline use in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose disease expresses the PD-L1 protein.
The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for olaparib (Lynparza) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
The FDA has granted pembrolizumab (Keytruda) an accelerated approval for the treatment of patients with hepatocellular carcinoma (HCC) who have previously received sorafenib (Nexavar), according to Merck, the manufacturer of the PD-1 inhibitor.
The fast pace of development in the immunotherapy and targeted therapy space has outstripped the availability of head-to-head comparative data for adjuvant melanoma treatment. Therefore, Hussein Tawbi, MD, PhD, recommended for healthcare professionals to communicate the relative merits and risks of both options to patients and making a shared decision.
Selinexor has been granted a fast track designation by the Food and Drug Administration (FDA) to treat previously treated patients with diffuse large B-cell lymphoma (DLBCL) who are ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor (CAR) T-cell therapy.
There is an increasing need for board-certified genetic counselors in the United States, says Stephanie A. Cohen, MS, LCGC, and she is looking to nurses to help improve patient access to hereditary cancer risk assessment and genetic testing.
The combination use of adjuvant dabrafenib (Tafinlar) plus trametinib (Mekinist) has continued to show a significant relapse-free survival benefit among patients with resected stage III BRAF-mutant melanoma.
Low NR2F1 expression in disseminated tumor cells (DTCs) that is found in bone marrow may be indicative of developing metastatic breast cancer, according to results of a study published in Breast Cancer Research.
Patients with advanced cancers associated with NTRK gene fusions showed an 80% objective response rate (ORR) with larotrectinib, a TRK inhibitor, according to pooled results from 3 small trials.
The FDA has approved elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor.
The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) as frontline maintenance therapy in women with BRCA-positive advanced ovarian cancer, according to findings reported at the 2018 European Society of Medical Oncology Congress.
Frontline alectinib (Alecensa), a next-generation tyrosine kinase inhibitor, enabled Asian patients with untreated ALK-positive advanced non–small cell lung cancer (NSCLC) to live significantly longer without disease progression compared with those who were treated with crizotinib (Xalkori) as initial therapy.
The Food and Drug Administration approved pegfilgrastim-cbqv (Udenyca), a biosimilar to pegfilgrastim (Neulasta).
After a computerized assessment, patients choose between traditional or virtual therapy.
The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinases inhibitors (TKIs).
Trifluridine/tipiracil (FTD/TPI; Lonsurf) reduced the risk of death in patients with heavily pretreated gastric or gastroesophageal junction (GEJ) cancer by 31% compared with placebo, according to data from the phase III TAGS trial.
A panel of experts gathered at a preconference presentation at the Association of Community Cancer Centers 35th National Oncology Conference in Phoenix to exchange their thoughts on the practical and theoretical considerations of incorporating biosimilars into the healthcare ecosystem.
Treatment for multiple myeloma is quickly evolving. To bring physicians, nurses, and other members of the community oncology care team up to date, Abhinav B. Chandra, MD, MSc, FACP, conducted a presentation at the Association of Community Cancer Centers (ACCC) 35th National Oncology Conference in Phoenix, Arizona.
Here are the top 5 Oncology Nursing News stories for October 2018.
At the Association of Community Cancer Centers (ACCC) 35th National Oncology Conference, Jessica Clague DeHart, PhD, MPH, discussed how clinicians can communicate the importance of physical activity and good nutrition practices to patients.
The FDA has approved pembrolizumab (Keytruda) for first-line use in combination with carboplatin and either paclitaxel or nab-paclitaxel (Abraxane) for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).
How can oncology teams become more resilient in the face of growing professional challenges?
